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Abstract
Objective: Platelet reactivity, platelet binding to monocytes and monocyte infiltration play a detrimental role in
atherosclerotic plaque progression. We investigated whether platelet reactivity was associated with levels of circulating
platelet-monocyte complexes (PMCs) and macrophages in human atherosclerotic carotid plaques.
Methods: Platelet reactivity was determined by measuring platelet P-selectin expression after platelet stimulation with
increasing concentrations of adenosine diphosphate (ADP), in two independent cohorts: the Circulating Cells cohort
(n = 244) and the Athero-Express cohort (n = 91). Levels of PMCs were assessed by flow cytometry in blood samples of
patients who were scheduled for percutaneous coronary intervention (Circulating Cells cohort). Monocyte infiltration was
semi-quantitatively determined by histological examination of atherosclerotic carotid plaques collected during carotid
endarterectomy (Athero-Express cohort).
Results: We found increased platelet reactivity in patients with high PMCs as compared to patients with low PMCs (median
(interquartile range): 4153 (1585–11267) area under the curve (AUC) vs. 9633 (3580–21565) AUC, P,0.001). Also, we
observed increased platelet reactivity in patients with high macrophage levels in atherosclerotic plaques as compared to
patients with low macrophage levels in atherosclerotic plaques (mean6SD; 896963485 AUC vs. 702063442 AUC, P = 0.02).
All associations remained significant after adjustment for age, sex and use of drugs against platelet activation.
Conclusion: Platelet reactivity towards ADP is associated with levels of PMCs and macrophages in human atherosclerotic
carotid plaques.
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Introduction
Platelets and monocytes play a crucial role in the initiation and
progression of atherosclerosis [1]. Platelets tether and roll over
inflamed endothelial cells through transient interactions between
platelet Glycoprotein Iba (GPIba) and endothelial P-selectin [2,3].
The role of platelet binding to inflamed endothelial cells during the
development of atherosclerosis was evidenced by a significant
reduction in monocyte accumulation and atherosclerotic plaque
progression after treatment with GPIba blocking antibodies [4].
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The interaction of platelets with inflamed endothelial cells also
facilitates the capturing of monocytes to the vessel wall through
interaction between Gp1ba and the constitutively expressed
monocyte receptor P-Selectin Glycoprotein Ligand-1 (PSGL-
1)[5]. This interaction, together with the interaction between
GPIba and the integrin macrophage-1 antigen (MAC-1), results in
firm cellular arrest of monocytes and their subsequent infiltration
into the vascular wall [6,7]. Besides the capturing of monocytes to
the vessel wall by interaction of monocytes with platelets that are
bound to inflamed endothelial cells, platelets also bind circulating
monocytes. Previous work has shown that formation of these
circulating platelet-monocyte complexes results in increased
infiltration of monocytes into atherosclerotic plaques in mice [8]
and elevated levels of circulating PMCs were observed in patients
with coronary artery disease [9–11].
Infiltration of monocytes into atherosclerotic plaques worsens
atherosclerosis. Monocytes migrate into atherosclerotic plaques,
where they differentiate into macrophages [12]. These macro-
phages secrete proteases and inflammatory proteins that weaken
the fibrous cap, which increases the risk of plaque rupture.
Rupture-prone plaques are characterized by a thin fibrous cap
covering a large lipid core that is enriched with macrophages.
Stable plaques contain less macrophages and are enriched with
smooth muscle cells and high amounts of collagen [3]. After
plaque rupture, platelets are activated and the formation of an
occlusive thrombus can occur.
The role of platelet activation in atherosclerotic disease
progression has been demonstrated by a reduction of cardiovas-
cular events after platelet inhibition therapies [13]. Moreover, P-
selectin knockout mice showed decreased monocyte adherence to
the vessel wall and hence decreased atherosclerotic plaque
formation [14,15]. Platelet activation is triggered through stimu-
lation of various receptors that stimulate integrin aIIbb3 activation,
which is crucial for platelet aggregation. Several assays that
measure platelet aggregation are currently available, e.g.; light
transmission aggregometry (LTA), VerifyNow and platelet func-
tion analysis system (PFA-100). We have optimized a whole blood
flow cytometry assay that measures platelet activation instead of
platelet aggregation [16]. Our assay is based on the platelet
response to increasing concentrations of adenosine diphosphate
(ADP), which was quantified by the measurement of P-selectin
upregulation after stimulation [17]. We used the platelet reactivity
assay to investigate whether the reactivity of platelets towards ADP
is associated with PMCs in circulation and macrophages in human
atherosclerotic carotid plaques.
Methods
Ethics statement
All research in this study was approved by the ethics committees
of the four participating medical centers in the Netherlands, being:
Catharina Hospital in Eindhoven, University Medical Center in
Maastricht, University Medical Center in Leiden and the
University Medical Center in Utrecht. The study conforms to
the Declaration of Helsinki and all participants provided written
informed consent prior to participation.
Study population
This report includes 2 cohorts: the Center for Translational
Molecular Medicine (CTMM) cohort and the Athero Express (AE)
cohort, executed at different laboratories in the Netherlands.
We analyzed 244 patients included in the CTMM cohort, who
were scheduled for percutaneous coronary intervention, as
previously described [18]. Exclusion criteria were age under 18
years, suspected alcohol or drug abuse, ST-elevation myocardial
infarction, serious concomitant disease, an infection or suspected
immune status elevation in six weeks prior to inclusion or absence
of cooperation. Patients were included between September 2009
and April 2011.
We investigated 91 patients from the AE cohort, who were
scheduled for carotid endarterectomy (CEA), as previously
described [19]. Indications for CEA were reviewed by a
multidisciplinary vascular team and were based on the recom-
mended criteria of the Asymptomatic Carotid Atherosclerosis
Study, the North American Symptomatic Carotid Endarterectomy
Trial (NASCET: ISRCTN57874028), and the European Carotid
Surgery Trial (ECST) [20,21]. Patients undergoing CEA in the
University Medical Center Utrecht were included between
January 2011 and July 2012.
Flow cytometry
Flow cytometry measurements were performed on the BD
FACS Canto II (BD Biosciences). All samples were measured
once. Compensation was calibrated using FITC and PE labeled
beads according to the manufacturers protocol (BD Biosciences),
and applied to all measurements. For the FITC signal, the solid
state blue laser was used with a 530/30 filter. The PE signal was
measured with the solid state blue laser and a 585/42 filter.
Samples were measured using a flow rate of 1.5 mL/sec and data
was acquired in a four-decade logarithmic scale. In the platelet
activation assay, a gate was applied in the SSC-H/FSC-H plot
around the GPIb+ (CD42b-FITC) cells. Within this gate, we
measured 10.000 events. A blood sample that was not stimulated
with a platelet agonist was used as a negative control to set the
threshold for P-selectin (CD62P-PE) expression. With this
threshold, we measured the increase in P-selectin median
fluorescence intensity after stimulation with increasing concentra-
tions of ADP. To measure PMCs, we gated CD14+ (CD14-PE)
cells within the SSC-H/FSC-H plot and measured 15.000 events
within this gate. Within this gate, the GPIb+ (CD42b-FITC) events
were measured. An isotype control was used as a negative control
for GPIb expression. Flow cytometry data was analyzed using
FACS Diva software (BD Biosciences).
Blood collection and platelet reactivity assay
Arterial blood samples were collected in citrate (3.2%)
anticoagulated tubes (BD Biosciences) prior to intervention and
processed directly after collection to prevent any potential blood
storage effects.
Platelet reactivity was quantified by stimulation with an
increasing concentration of ADP, ranging from 8 nM to
125 mM. The serial dilutions were prepared in 50 mL HEPES
buffered saline (HBS; 10 mM HEPES, 150 mM NaCl, 1 mM
MgSO4, 5 mM KCl, pH 7.4) to which 2 mL CD62P-PE (550561,
BD Biosciences) and 2 mL CD42b-FITC (555472, BD Biosciences)
mouse anti-human antibodies were added. The platelet reactivity
assay was initiated by the addition of 5 mL whole blood to each
sample of the serial dilution for 20 minutes at room temperature.
Samples were fixated with 500 mL of 0.2% formaldehyde in 0.9%
NaCl solution. Using flow cytometry, 10.000 platelets were
identified by scatter gating and CD42b-FITC binding, after which
CD62P-PE mean fluorescence intensity (MFI) was measured. We
used the area under the curve (AUC) to integrate the sensitivity
and the maximum response of platelets towards agonist concen-
trations into one quantitative value (Figure 1). All data acquisition
was performed with the CXP SYSTEM software.
Platelet Reactivity in Atherosclerosis
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Measurement of PMCs in the CTMM cohort
Circulating PMCs were quantified with a mixture of 40 mL
HEPES buffered saline (HBS; 10 mM HEPES, 150 mM NaCl,
1 mM MgSO4, 5 mM KCl, pH 7.4) to which 5 mL CD14-PE
(555398, BD Biosciences) and 5 mL CD42b-FITC (555472, BD
Biosciences) mouse anti-human antibodies were added. Subse-
quently, 50 mL of whole blood was added to the mixture for 30
minutes at room temperature. Samples were fixated with 80 mL of
Optilyse B (Beckman Coulter), containing 3.4% paraformaldehyde
for 10 minutes, after which red blood cells were lysed by the
addition of 825 mL of demineralized water. Monocytes were
identified by scatter gating and CD14 labeling. PMCs were
determined by the percentage of monocytes that were positive for
the platelet marker CD42b-FITC. Fifteen thousand cells were
counted on the same day of processing and data acquisition was
performed with the CXP SYSTEM software.
Histological examination of macrophages in
atherosclerotic carotid plaques in the AE cohort
Atherosclerotic carotid plaques were collected during CEA and
immediately transported to the laboratory for processing. Using a
standardized protocol, plaques were divided in 5-mm segments
along the longitudinal axis, followed by fixation with 4%
paraformaldehyde and embedment in paraffin. The segment with
the largest plaque burden was defined as the culprit lesion.
Subsequent histological plaque assessment was performed by an
experienced technician, blinded for patient characteristics or
clinical outcome, with a good inter- and intraobserver variability
[22]. Macrophages were identified by CD68 labeling and semi-
quantitatively categorized in two categories, being low and high
staining, at original magnification x40. Plaques were categorized
as low macrophage staining if staining was negative or clusters
with ,10 cells were present. Cell clusters .10 cells or abundance
of positive cells were categorized as high staining.
Statistical analysis
Patients included in the CTMM cohort were divided into
groups with low or high levels of PMCs based on the median value
of these complexes. The CTMM platelet reactivity values were not
normally distributed, therefore we used the non-parametric Mann-
Whitney U test to compare platelet reactivity levels between
patients in the low and high levels of PMCs groups. For the same
reason, platelet reactivity values were transformed into natural
logarithmic values and adjusted for age, sex and acetylsalicylic acid
use in univariate analysis of variance. Since previous research
demonstrated reduced platelet reactivity and PMC formation in
patients treated with clopidogrel [23,24], we performed a
subanalysis after stratification on clopidogrel use.
Patients included in the AE cohort were divided into groups
with low or high levels of macrophages in plaques based on semi-
quantitative analysis. AE platelet reactivity values were normally
distributed. Therefore, we used the parametric Student’s t-test to
compare levels of platelet reactivity between patients in the low or
high macrophage groups and logarithmic transformation was not
necessary. Hereafter, AE platelet reactivity values were adjusted
for age, sex, acetylsalicylic acid and clopidogrel use in univariate
analysis of variance. Because 9 patients (10%) were treated with
clopidogrel, of which only 1 patient had a plaque with a high level
of macrophages, we did not separately assess clopidogrel-treated
and non-treated patients.
All statistical analyses were performed using SPSS version 20.0
software (IBM Corp, IBM SPSS Statistics for Windows, Armonk,
NY) and a two-sided P-value ,0.05 was considered statistically
significant.
Figure 1. Conversion of dose-response curve into area under the curve. In order to compare total platelet reactivity between patients, we
derived the area under the curve from each dose response curve. MFI =mean fluorescence intensity, AUC= area under curve, ADP= adenosine
diphosphate.
doi:10.1371/journal.pone.0105019.g001
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Results
Baseline characteristics
The baseline characteristics and medication use at inclusion of
patients investigated in the CTMM cohort (n = 244) and in the AE
cohort (n = 91) are shown in table 1.
In the CTMM cohort, 189 patients (77.5%) were presenting
with stable angina and 32 patients (13.3%) with unstable angina
and 23 patients (9.5%) with nSTEMI. Subjects with stable angina
had lower mean cholesterol levels (P = 0.03) and a higher
prevalence of renal failure (P = 0.01) as compared with subjects
with unstable angina, while subjects with nSTEMI used nitrates
less frequently (P = 0.05) as compared with subjects with stable
angina. CTMM patients were divided into groups with high
(n = 122) and low levels of PMCs (n = 122) based on the median
level of PMCs.
In the AE cohort, 75 patients (84%) had symptomatic carotid
artery disease. AE patients were divided into groups with high
(n = 24) and low (n= 67) levels of macrophages in the carotid
plaques.
No significant differences were observed in baseline character-
istics between patients in the high versus low groups within the
CTMM and AE cohort. Moreover, no significant differences in
baseline P-selectin expression before platelet stimulation with ADP
were observed between the two groups within both cohorts (data
not shown).
High platelet reactivity is associated with increased levels
of PMCs
In the CTMM cohort, we found a higher AUC after platelet
stimulation with ADP in patients with high levels of PMCs as
compared to patients with low levels of PMCs (median (inter-
quartile range (IQR)); 9633 (3580–21565) AUC vs. 4153 (1585–
11267) AUC, P,0.001) (Figure 2, Table S1). These associations
remained significant after natural logarithmic transformation and
adjustment for age, sex, acetylsalicylic acid and clopidogrel use
(Table S1).
Next, we compared the AUC after platelet stimulation between
patients not treated with clopidogrel to patients treated with
clopidogrel. We found a higher AUC in patients not treated with
clopidogrel (n = 109) as compared to patients treated with
clopidogrel (n = 131) (median (IQR); 9784 (3206–21955) AUC
vs. 5329 (866–11430) AUC, P=0.001) (Table S2). Subsequently,
we stratified patients on clopidogrel use and performed a sub
analysis. In patients treated with clopidogrel, a higher AUC was
found in patients with high levels of PMCs (n = 64) as compared to
patients with low levels of PMCs (n= 67) (median (IQR); 2252
(1408–2784) AUC vs. 1447 (942–2329) AUC, P= 0.002) (Table
S2). In patients not treated with clopidogrel, we also found a
higher AUC in patients with high levels of PMCs (n = 57) as
compared to patients with low levels of PMCs (n = 52) (median
(IQR); 2878 (1866–3330) AUC vs. 1881 (1035–2793) AUC,
P= 0.009) (Table S2).
Table 1. Baseline characteristics.
CTMM population AE population
(n =244) (n =91)
Age in years 6369.7 71.669.5
Male sex 167/244 (69%) 66/91 (73%)
Body mass index (kg/m2) 27.764.5 25.465.1
Smoking 53/244 (22%) 31/88 (35%)
Diabetes mellitus 45/244 (19%) 18/91 (20%)
Hypertension 157/244 (65%) 54/88 (61%)
Dyslipidemia 155/244 (64%) 53/75 (71%)
Total cholesterol (mmol/L) 4.461.2 4.961.5
History of coronary artery disease 115/244 (48%) 36/91 (40%)
Kidney disease 6/244 (3%) NA
Glomerular Filtration Rate, CG, (mL/min) NA 69.2624.5
Acetylsalicylic acid 198/244 (83%) 73/89 (82%)
Clopidogrel 131/244 (55%) 9/89 (10%)
Dipyridamole Not available 62/90 (69%)
Statins 192/244 (80%) 77/90 (86%)
Nitrates 88/244 (37%) Not available
Clinical presentation Not applicable
Asymptomatic 14/89 (16%)
Amaurosis fugax 23/89 (26%)
Transient ischemic attack 26/89 (29%)
Stroke 26/89 (29%)
Bilateral carotid stenosis (.50%) Not applicable 33/72 (47%)
Days from clinical event to CEA (median [IQR]) Not applicable 18 [11–31]
Continuous values are expressed as mean 6 standard deviation (unless specified otherwise). Categorical values are expressed as number of total (percentage).
CG=Cockroft-Gault, CEA= carotid endarterectomy, IQR= interquartile range.
doi:10.1371/journal.pone.0105019.t001
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Next, we adjusted for age, sex and acetylsalicylic acid. All
associations between platelet reactivity and levels of PMCs
remained significant in both clopidogrel-treated patients
(mean6SD, 20516933 AUC vs. 15506933AUC, P= 0.003)
and non-treated patients (mean6SD, 252161120 vs.
194561121, P= 0.009) (Table S2).
High platelet reactivity is associated with high levels of
macrophages in atherosclerotic carotid plaques
In the AE cohort, we observed a higher AUC after platelet
stimulation with ADP in patients with high levels of macrophages
in atherosclerotic carotid plaques as compared to patients with low
levels of macrophages in atherosclerotic carotid plaques
(mean6SD, 925564530 AUC vs. 699563406 AUC, P= 0.01)
(Figure 3, Table S3). Adjustment for age, sex, acetylsalicylic acid
and clopidogrel use did not change the association between
platelet reactivity and macrophages in atherosclerotic plaques
(mean6SD, 896963485 vs. 702063442, P = 0.02) (Table S3).
Figure 4 shows representative images of carotid plaques with
low (Figure 4a, with higher magnification in 4b) and high
(Figure 4c, with higher magnification in 4d) amounts of macro-
phages in the plaque.
Discussion
In patients referred for percutaneous coronary intervention, we
found that high platelet reactivity was associated with high levels of
circulating PMCs. In patients undergoing carotid endarterectomy,
we observed that high platelet reactivity was associated with high
levels of macrophages in atherosclerotic carotid plaques. All
associations were found to be independent of age, sex and the use
of drugs that inhibit platelet activation.
We determined platelet reactivity by measuring P-selectin
upregulation after stimulation with increasing concentrations of
ADP, using flow cytometry [17]. ADP activates platelets via the
P2Y12 and P2Y1 receptors, which have been implicated as
important mediators of atherosclerosis [25,26]. Inflamed endo-
thelium does not induce excessive platelet activation, and,
similarly, ADP is a mild activator of platelet activation. Moreover,
previous work from our department shows that measurement of
Figure 2. Platelet reactivity related to platelet-monocyte complexes. Comparison of the AUC after ADP stimulation between low (n= 122)
versus high levels of platelet-monocyte complexes (n = 122). Grey bars represent medians with interquartile ranges. MFI =mean fluorescence
intensity, AUC= area under curve, ADP= adenosine diphosphate.
doi:10.1371/journal.pone.0105019.g002
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Figure 3. Platelet reactivity related to macrophage levels. Comparison of the AUC after ADP stimulation between low (n= 67) versus high
macrophage levels in atherosclerotic carotid plaques (n = 24). Grey bars represent means with standard deviations. MFI =mean fluorescence intensity,
AUC= area under curve, ADP= adenosine diphosphate.
doi:10.1371/journal.pone.0105019.g003
Figure 4. Histology of macrophage levels in atherosclerotic carotid plaques. Macrophage staining (brown), nucleus staining with
haematoxylin (blue). (a) Low macrophage levels (406magnification). (b) Higher magnification of the indicated area in (a) (1006magnification). (c)
High macrophage levels (406magnification). (d) Higher magnification of the indicated area in (c) (1006magnification).
doi:10.1371/journal.pone.0105019.g004
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platelet reactivity towards a mild activator like ADP is more likely
to differ between cases and controls than stronger activators like
thrombin receptor activating peptide (TRAP), collagen related
peptide (CRP) or convulxin (a snake venom toxin that activates
platelets) [27]. Hence, we feel that ADP is a suitable agonist that
represents in vivo platelet stimulation. We used P-selectin as a
marker of platelet activation, because P-selectin is translocated
from the inner a-granule membrane to the outer platelet cell
membrane after platelet activation. For this reason, P-selectin
expression on the platelet cell membrane is currently the most
commonly used marker of platelet activation.
The majority of commercially available platelet function assays,
which have been questioned regarding their sensitivity and
reproducibility [28–31], measure platelet aggregation. In contrast
to these assays, we measure platelet reactivity. Evidence for a role
of platelet reactivity in the progression of atherosclerosis was
previously shown by infusion of activated platelets into ApoE
knockout mice. The infused activated platelets adhered to
monocytes, which resulted in increased atherosclerotic lesion size
[8]. The mechanism by which platelets play a role in monocyte
infiltration depends on the interaction between P-selectin on the
platelet membrane and P-Selectin Glycoprotein Ligand-1 (PSGL-
1) on the monocyte cell membrane. The binding of P-selectin to
PSGL-1 induces the activation of integrins on the monocyte cell
membrane, which results in enhanced adhesion of monocytes to
inflamed endothelial cells [32,33]. Also, the release of potent
inflammatory proteins from the platelet a-granule during activa-
tion enhances the adhesive and chemotactic properties of
endothelial cells [34,35] and the release of monocyte chemoat-
tractants, such as PF4 and RANTES, contributes to the infiltration
of monocytes into atherosclerotic plaques [36–38]. The release of
a-granule proteins is dependent on platelet reactivity towards
agonists, but the relationship between platelet reactivity, PMC
formation and macrophages in atherosclerotic carotid plaques has
not yet been fully investigated. Previously it was shown that levels
of circulating PMCs and percentages of platelets expressing P-
selectin after stimulation were increased in 19 patients with stable
angina compared to 19 healthy control subjects [10]. We extend
these results by showing, in a population of 244 coronary artery
disease patients, an independent association between high P-
selectin expression after ADP stimulation and increased levels of
circulating PMCs. Additionally, we show in 91 carotid endarter-
ectomy patients that high P-selectin expression is associated with
increased monocyte infiltration into atherosclerotic carotid
plaques, independent of investigated covariates.
Clopidogrel, which blocks P2Y12 receptors, is used to prevent
platelet aggregation in cardiovascular diseases. In the AE cohort,
only 10% of the patients received clopidogrel, while, in the
CTMM cohort, 55% of the patients received clopidogrel. Due to
the P2Y12 block, platelets are less sensitive towards ADP
stimulation. Affirmatively, we found a significant decrease in the
AUC after platelet stimulation with ADP when clopidogrel users
were compared with non-clopidogrel users in the CTMM cohort.
However, we observed no significant differences in levels of PMCs
when clopidogrel users were compared with non-clopidogrel users
(data not shown). Importantly, even though clopidogrel use
decreased platelet activation, the association between platelet
reactivity and levels of PMCs remained significant. In the AE
cohort, 9 patients received clopidogrel, of which only one had a
plaque with high infiltration of macrophages. Hence, we could not
analyze the effect of clopidogrel on levels of macrophages in
plaques. Within both cohorts, no patients were treated with other
P2Y12 inhibiting drugs, like cangrelor or prasugrel.
A limitation of this study is that levels of PMCs and levels of
macrophages in atherosclerotic plaques were not assessed in both
the CTMM cohort and the AE cohort, which included patients
with different vascular diseases. Therefore we could not study
whether platelet reactivity, levels of PMCs and levels of
macrophages in atherosclerotic plaques were directly linked to
each other. Nevertheless, the independent associations that we
found in these two cohorts of patients with different vascular
diseases, underscore the potential role of platelet reactivity in
cardiovascular disease.
In conclusion, our observations show that increased platelet
reactivity is independently associated with increased levels of
circulating PMCs and macrophages in human atherosclerotic
carotid plaques. This may suggest that decreased levels of
circulating PMCs and macrophages in atherosclerotic plaques
might be achieved by platelet inhibition.
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